Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS) is participating in the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The virtual fireside chat will feature key executives, including President and CEO William Collier and Chief Scientific Officer Dr. Michael Sofia. The chat will be accessible via the company's website starting at 6:00 am EST on January 11, 2021. Arbutus focuses on developing treatments for chronic hepatitis B virus (HBV) and coronaviruses like COVID-19, with multiple drug candidates in progress.
- None.
- None.
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference taking place from January 11 – 14, 2021.
Arbutus Fireside Chat Presenters:
William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer.
A webcast of the virtual fireside chat will be available starting at 6:00 am (EST) on January 11, 2021, and can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com
FAQ
When will Arbutus Biopharma participate in the H.C. Wainwright BioConnect 2021 Conference?
Who are the presenters at the Arbutus virtual fireside chat?
What time does the Arbutus fireside chat start on January 11, 2021?
Where can I watch the Arbutus Biopharma webcast?
What is the focus of Arbutus Biopharma's research?
